Eosinophilia resulting from administration of recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in a patient with T-gamma lymphoproliferative disease |
| |
Authors: | R Gonzales-Chambers C Rosenfeld A Winkelstein L Dameshek |
| |
Affiliation: | Department of Internal Medicine, University of Pittsburgh, School of Medicine, Pennsylvania. |
| |
Abstract: | A therapeutic trial of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was attempted in a patient with neutropenia and frequent infections secondary to T-gamma lymphoproliferative disease (T-gamma LPD). During the 14 days of subcutaneous rhGM-CSF (500 micrograms/m2/day), the absolute eosinophil count increased from 0 to 9,455/microliters. By contrast, the absolute neutrophil count decreased. Toxicity related to rhGM-CSF included arthralgia and nonspecific chest pain. The possible mechanism for the rhGM-CSF induced selective eosinophilia is discussed. |
| |
Keywords: | colony-stimulating factor lymphoproliferative disorders |
|